Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cynthia Matossian

Ophthalmology Pennington, NJ Medical Doctor

NPI 1689635807 CMS profile 211790

2 Capital Way, Suite 326, Pennington, NJ 08534

Open in the dashboard

General payments

$654,949

769 records reported · program years 2019–2025

Research payments

$14,614

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$440,302

15 holdings reported · through program year 2025

Research they led as principal investigator

$71,528 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Cynthia Matossian of Pennington, NJ is reported in the CMS Open Payments database as having received $654,949 across 769 general payments and $14,614 in research payments paid to them. Separately, studies naming them as principal investigator received $71,528 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $440,302 across 15 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,174 52
2024 General $62,534 85
2023 General $76,743 97
2022 General $93,831 128
2022 Research $10,614 2
2021 General $76,907 111
2020 General $144,328 111
2019 General $159,431 185
2019 Research $4,000 1
2024 Ownership $96,667 2
2023 Ownership $96,667 2
2022 Ownership $96,667 2
2021 Ownership $60,257 4
2020 Ownership $60,032 3
2019 Ownership $30,013 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cynthia Matossian
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Cynthia Matossian were reported at $41,174. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Cynthia Matossian Ophthalmology median Middle half National median
2019 $159,431 $258 $104–$655 $163
2020 $144,328 $126 $45–$321 $114
2021 $76,907 $205 $76–$534 $132
2022 $93,831 $266 $100–$678 $149
2023 $76,743 $308 $117–$745 $160
2024 $62,534 $340 $127–$846 $164
2025 $41,174 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $137,011 167 payments
  2. Johnson & Johnson Surgical Vision, Inc. $102,399 89 payments
  3. Sun Pharmaceutical Industries Inc. $100,321 98 payments
  4. EyePoint Pharmaceuticals US, Inc. $82,434 41 payments
  5. Carl Zeiss Meditec, Inc. $38,125 27 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $37,993 74 payments
  7. Alcon Vision LLC $24,705 29 payments
  8. Kala Pharmaceuticals, Inc. $18,243 13 payments
  9. Sight Sciences, Inc. $15,586 22 payments
  10. Quidel Corporation $11,400 37 payments
  11. Other $86,733 172 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $369,758 177 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $79,125 27 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $72,015 26 payments
  4. Honoraria $31,150 15 payments
  5. Food and Beverage $27,891 418 payments
  6. Travel and Lodging $27,334 99 payments
  7. Gift $23,776 1 payment
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $13,900 4 payments
  9. Charitable Contribution $10,000 2 payments
Products named General payments · program years 2019–2025
  1. Cequa $97,634 92 payments
  2. DEXYCU $79,051 36 payments
  3. MIEBO $71,255 81 payments
  4. XIIDRA $44,349 47 payments
  5. Crystalens Accommodating IOL (AT-52AO) $39,385 67 payments
  6. Whitestar Phacoemulsficiation System $31,250 8 payments
  7. Catalys Laser System $31,250 8 payments
  8. One Series Ultra IOL Delivery System $31,250 8 payments
  9. Unfolder IOL Delivery Systems $31,250 8 payments
  10. Akreos AO IOL $29,810 51 payments
  11. Other $532,203 806 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $7,275 1 payment
  2. Johnson & Johnson Surgical Vision, Inc. $4,000 1 payment
  3. Oyster Point Pharma, Inc. $3,339 1 payment

Records

772 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record